TM791
Zellname |
Beschreibung |
Bestell-Nr. |
Einheit |
Preis, Euro |
|---|---|---|---|---|
TM791 |
Humane Osteosarkom Zell-Linie |
300358 |
cryovial |
375,00 |
TM791 |
Humane Osteosarkom Zell-Linie |
330358 |
vital |
465,00 |
| Designation: | TM791 |
| Depositor: | Klein |
| Organism: | Homo sapiens (human) |
| Gender: | Female |
| Tissue: | (Bone) |
| Celltype: | (Osteosarcoma) |
| Growth Properties: | Monolayer |
| Description: | Authentication of this cell line has revealed that the STR profile of TM791 is almost identical to HeLa and KB. Thus, the origin of this cell line remains unclear. |
| Culture Medium: | DMEM:Ham's F12 medium supplemented with 2 mM L-glutamine and 10% heat-inactivated horse serum |
| Subculturing: | Remove medium, add fresh 0.025% trypsin, 0.02% EDTA solution for 1 to 2 minutes, remove trypsin and let the culture sit at room temperature (or at 37°C) until the cells detach (about 10 minutes). Add fresh medium, aspirate and dispense into new flasks. |
| Split Ratio: | A ratio of 1:3 to 1:5 is recommended |
| Fluid Renewal: | 1-2 times weekly |
| Freeze Medium: | CM-1 (Cell Lines Service) |
| Sterility: | Tests for mycoplasma(PCR, DAPI), bacteria and fungi (fluoresence) were negative. |
| DNA Profile (STR): | Amelogenin: X / X CSF1PO: 9/10 D13S317: 12 / 13.3 D16S539: 9/10 D5S818: 11/12 D7S820: 8/12 THO1: 7 TPOX: 8/12 vWA: 16 D3S1358: 15/18 D21S11: 27/28 D18S51: 16 Penta E: 7/17 Penta D: 8/15 D8S1179: 13 FGA: 18/21 CLS ∙ Cell Lines Service, 2011. |
| Products: | GAPDH PCR product |
References: Mengede C., Vukovic V., Glüsenkamp K.-H., Jähde E. and Rajewsky M.P. Development of acid-labile immunoconjugates for tumor-specific activation of cytotoxins. Journal of Cancer Research and Clinical Oncology, 121, Supplement 1, A52, D0I: 10.1007/BF02572172, 1995. Lixin Liu. 216. Dissertation: Analysis of the ETAA16 Expression.. Zentrum für Kinderheilkunde der Universität Düsseldorf. Klinik für Pädiatrische Hämatologie, 2001. K. Bienemann. Dissertation: Entwicklung einer tumorspezifischen Suizidtherapie für Osteosarkome. Klinik für Pädiatrische Hämatologie, Onkologie und Immunologie der Heinrich Heine Universität Düsseldorf, 2005. | |
